Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tranexamic Acid Injectable Product

Phase 1

TThe University of Texas Health Science Center at San Antonio

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Hemorrhage, SurgicalRecruiting

Hemorrhage, SurgicalPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Hemorrhage, Surgical

NCT07565753

Clinical

Trials by Indication[1]

Hemorrhage, Surgical1 trial

TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage (TEAPOT): A Multi-center Feasibility Study

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT07565753·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tranexamic Acid Injectable Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tranexamic Acid Injectable Product. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — The University of Texas Health Science Center at San Antonio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: TThe University of Texas Health Science Center at San Antonio

Related News